Abstract: The present invention relates to methods for the detection and quantification of apolipoproteins and isoforms thereof in a sample, as well as to predictive methods of the probability of neurodegenerative or cardiovascular disease development based on apolipoprotein levels as determined by the detection methods of the invention.

Abstract: The present invention relates to a Raman spectroscopy method for determining protein structure associated with global cognitive deterioration in Alzheimer's disease from the Raman spectroscopic analysis of a human blood sample, preferably of a human blood plasma sample, comprising obtaining at least one spectral value of at least one of the Raman spectrum regions comprised between 1600-1700 cm?1, between 910-980 cm?1, between 730-760 cm?1 and/or between 390-450 cm?1, and where said spectral value allows obtaining an indication of the presence or absence of protein structure associated with a condition of Alzheimer's disease. The present invention also relates to a method for the infrared spectroscopic analysis of a blood sample, by means of additionally obtaining at least one spectral value of at least one of the infrared spectrum regions comprised between 1600 and 1700 cm?1, and/or between 1000 and 1150 cm?1 and/or between 1140 and 1190 cm?1.

Abstract: The present invention relates to a method for transmission infrared spectroscopic analysis for determining the degree of global cognitive impairment associated with Alzheimer's disease based on analyzing the 3100-1300 cm?1 infrared spectrum region of a previously obtained and fractionated sample of blood. Preferably, the fractionated sample of blood to be analyzed is a fraction of leukocytes. Likewise, another object of the present invention relates to the use of said method to obtain an indication of the status of the Alzheimer's disease and/or an indication of the degree of cognitive impairment associated with said disease.